Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: A multicentre, single-blind, prospective trial

ÖZAKBAŞ S., Cinar B. P., Kosehasanogullari G., Kahraman T., Oz D., Kursun B. B.

CLINICAL NEUROLOGY AND NEUROSURGERY, vol.160, pp.69-72, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 160
  • Publication Date: 2017
  • Doi Number: 10.1016/j.clineuro.2017.06.016
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.69-72
  • Keywords: Relapsing remitting multiple sclerosis, Pulse methylprednisolone, Expanded disease status scale, Disability, DISABILITY STATUS SCALE, MS
  • Dokuz Eylül University Affiliated: Yes


Objectives: Multiple sclerosis is usually clinically characterized by repeated subacute relapses followed by remissions. Corticosteroids are used for relapses, and this treatment has been shown to increase the speed of recovery from these. We aimed to evaluate the efficacy and safety of pulsed methylprednisolone given every month as an add-on therapy to interferon beta or glatiramer acetate in patients with relapsing-remitting multiple sclerosis.